Plant Name: Actaea dahurica
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
| Cytochrome P450 Enzymes: |
|---|
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0005488; binding | GO:0008270; zinc ion binding | 3.280E-13 | 7.142E-10 | CA1, CA12, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9, MMP1, MMP2, MMP9, PPARA, PPARD, PTPN1, TP53 |
| BP | GO:0008152; metabolic process | GO:0019433; triglyceride catabolic process | 2.362E-07 | 2.143E-04 | FABP2, FABP3, FABP4, FABP5 |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 1.665E-27 | 3.625E-23 | CA1, CA12, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
| CC | GO:0016020; membrane | GO:0016323; basolateral plasma membrane | 2.892E-06 | 1.536E-03 | CA2, CA4, CA9, SLC22A6, SLC22A8, TSHR |
| BP | GO:0050896; response to stimulus | GO:0010038; response to metal ion | 5.153E-06 | 2.387E-03 | ALOX15, CA2, FABP4, HIF1A, MAPK1, MMP9, TP53 |
| BP | GO:0009987; cellular process | GO:0010647; positive regulation of cell communication | 5.574E-06 | 2.516E-03 | ALOX15, CA2, CA7, CASP1, FFAR1, HIF1A, MAPK1, MMP9, NFKB1, PPARD, PTPN1, TLR2, TP53, XDH |
| BP | GO:0050896; response to stimulus | GO:0009719; response to endogenous stimulus | 5.766E-06 | 2.516E-03 | CA2, CA9, CASP7, FABP3, MAPK1, MMP2, NFKB1, PPARA, TLR2, TP53, TSHR |
| BP | GO:0023052; signaling | GO:0023056; positive regulation of signaling | 5.856E-06 | 2.516E-03 | ALOX15, CA2, CA7, CASP1, FFAR1, HIF1A, MAPK1, MMP9, NFKB1, PPARD, PTPN1, TLR2, TP53, XDH |
| BP | GO:0009987; cellular process | GO:0050714; positive regulation of protein secretion | 1.106E-05 | 4.279E-03 | ACHE, CASP1, FFAR1, HIF1A, PPARD, TLR2 |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 1.383E-05 | 5.103E-03 | CA2, CA7 |
| BP | GO:0050896; response to stimulus | GO:0033993; response to lipid | 1.995E-05 | 6.684E-03 | CA2, CA9, CASP1, FABP3, FFAR1, NFKB1, PPARD, TLR2, TP53 |
| BP | GO:0050896; response to stimulus | GO:0014070; response to organic cyclic compound | 2.107E-05 | 6.911E-03 | CA2, CA9, CASP1, CASP7, MAPK1, NFKB1, SLC22A6, TLR2, TP53 |
| BP | GO:0008152; metabolic process | GO:0009299; mRNA transcription | 2.126E-05 | 6.911E-03 | HIF1A, PPARD, TP53 |
| BP | GO:0050896; response to stimulus | GO:0042060; wound healing | 2.329E-05 | 7.407E-03 | ALOX15, PPARA, PPARD, TP53 |
| BP | GO:0050896; response to stimulus | GO:0042493; response to drug | 2.347E-05 | 7.407E-03 | CA3, CA9, CASP1, FABP3, MAPK1, NFKB1, SLC22A6, TLR2, TP53 |
| BP | GO:0050896; response to stimulus | GO:1901701; cellular response to oxygen-containing compound | 2.838E-05 | 8.604E-03 | CASP1, MAPK1, MMP2, MMP9, NFKB1, PPARD, TLR2, TP53, TSHR |
| BP | GO:0008152; metabolic process | GO:0032963; collagen metabolic process | 2.845E-05 | 8.604E-03 | HIF1A, MMP1, MMP2, MMP9 |
| BP | GO:0032501; multicellular organismal process | GO:0001816; cytokine production | 3.132E-05 | 9.217E-03 | CASP1, FABP4, HIF1A, TLR2 |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 8.963E-21 | 9.758E-17 | CA1, CA12, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 1.809E-19 | 9.848E-16 | CA1, CA12, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 1.027E-26 | 1.540E-24 | CA12; CA1; CA3; CA5B; CA2; CA5A; CA4; CA7; CA6; CA9; CA14 |
| hsa03320 | PPAR signaling pathway_Homo sapiens_hsa03320 | 1.043E-10 | 7.824E-09 | FABP2; FABP3; FABP4; FABP5; MMP1; PPARA; PPARD |
| hsa05219 | Bladder cancer_Homo sapiens_hsa05219 | 2.263E-08 | 1.131E-06 | MMP1; MMP2; MAPK1; MMP9; TP53 |
| hsa05200 | Pathways in cancer_Homo sapiens_hsa05200 | 1.469E-06 | 5.509E-05 | MMP1; MMP2; MAPK1; HIF1A; TP53; MMP9; NFKB1; PPARD |
| hsa05205 | Proteoglycans in cancer_Homo sapiens_hsa05205 | 3.929E-06 | 1.179E-04 | MMP2; MAPK1; TP53; HIF1A; MMP9; TLR2 |
| hsa05134 | Legionellosis_Homo sapiens_hsa05134 | 5.300E-06 | 1.325E-04 | CASP7; CASP1; NFKB1; TLR2 |
| hsa04210 | Apoptosis_Homo sapiens_hsa04210 | 1.081E-05 | 2.315E-04 | CASP7; LMNA; MAPK1; TP53; NFKB1 |
| hsa05161 | Hepatitis B_Homo sapiens_hsa05161 | 1.324E-05 | 2.483E-04 | MAPK1; TP53; MMP9; NFKB1; TLR2 |
| hsa05133 | Pertussis_Homo sapiens_hsa05133 | 1.832E-05 | 3.054E-04 | CASP7; CASP1; MAPK1; NFKB1 |
| hsa04668 | TNF signaling pathway_Homo sapiens_hsa04668 | 8.253E-05 | 1.125E-03 | CASP7; MAPK1; MMP9; NFKB1 |
| hsa05160 | Hepatitis C_Homo sapiens_hsa05160 | 1.720E-04 | 1.984E-03 | MAPK1; PPARA; TP53; NFKB1 |
| hsa05221 | Acute myeloid leukemia_Homo sapiens_hsa05221 | 2.328E-04 | 2.328E-03 | MAPK1; NFKB1; PPARD |
| hsa00983 | Drug metabolism - other enzymes_Homo sapiens_hsa00983 | 1.228E-04 | 1.534E-03 | CYP2A6; CYP3A4; XDH |
| hsa05212 | Pancreatic cancer_Homo sapiens_hsa05212 | 3.594E-04 | 3.131E-03 | MAPK1; TP53; NFKB1 |
| hsa04621 | NOD-like receptor signaling pathway_Homo sapiens_hsa04621 | 2.328E-04 | 2.328E-03 | CASP1; MAPK1; NFKB1 |
| hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 3.436E-04 | 3.131E-03 | CYP2A6; ALDH1A1; CYP3A4 |
| hsa05230 | Central carbon metabolism in cancer_Homo sapiens_hsa05230 | 3.757E-04 | 3.131E-03 | MAPK1; TP53; HIF1A |
| hsa05220 | Chronic myeloid leukemia_Homo sapiens_hsa05220 | 4.835E-04 | 3.454E-03 | MAPK1; TP53; NFKB1 |
| hsa04024 | cAMP signaling pathway_Homo sapiens_hsa04024 | 7.919E-04 | 5.164E-03 | MAPK1; PPARA; NFKB1; TSHR |
| hsa05140 | Leishmaniasis_Homo sapiens_hsa05140 | 4.835E-04 | 3.454E-03 | MAPK1; NFKB1; TLR2 |
| hsa05215 | Prostate cancer_Homo sapiens_hsa05215 | 8.625E-04 | 5.391E-03 | MAPK1; TP53; NFKB1 |
| hsa04976 | Bile secretion_Homo sapiens_hsa04976 | 4.456E-04 | 3.454E-03 | CA2; SLC22A8; CYP3A4 |
| hsa04933 | AGE-RAGE signaling pathway in diabetic complications_Homo sapiens_hsa04933 | 1.244E-03 | 6.910E-03 | MMP2; MAPK1; NFKB1 |
| hsa04915 | Estrogen signaling pathway_Homo sapiens_hsa04915 | 1.174E-03 | 6.773E-03 | MMP2; MAPK1; MMP9 |
| hsa05132 | Salmonella infection_Homo sapiens_hsa05132 | 7.807E-04 | 5.164E-03 | CASP1; MAPK1; NFKB1 |
| hsa04066 | HIF-1 signaling pathway_Homo sapiens_hsa04066 | 1.316E-03 | 6.999E-03 | MAPK1; HIF1A; NFKB1 |
| hsa04620 | Toll-like receptor signaling pathway_Homo sapiens_hsa04620 | 1.429E-03 | 7.147E-03 | MAPK1; NFKB1; TLR2 |
| hsa05142 | Chagas disease (American trypanosomiasis)_Homo sapiens_hsa05142 | 1.353E-03 | 6.999E-03 | MAPK1; NFKB1; TLR2 |
| hsa04931 | Insulin resistance_Homo sapiens_hsa04931 | 1.549E-03 | 7.494E-03 | PTPN1; PPARA; NFKB1 |
| hsa05145 | Toxoplasmosis_Homo sapiens_hsa05145 | 1.943E-03 | 8.266E-03 | MAPK1; NFKB1; TLR2 |
| hsa04919 | Thyroid hormone signaling pathway_Homo sapiens_hsa04919 | 1.943E-03 | 8.266E-03 | MAPK1; TP53; HIF1A |
| hsa04722 | Neurotrophin signaling pathway_Homo sapiens_hsa04722 | 2.039E-03 | 8.266E-03 | MAPK1; TP53; NFKB1 |
| hsa05206 | MicroRNAs in cancer_Homo sapiens_hsa05206 | 3.422E-03 | 1.316E-02 | MAPK1; TP53; MMP9; NFKB1 |
| hsa04071 | Sphingolipid signaling pathway_Homo sapiens_hsa04071 | 2.039E-03 | 8.266E-03 | MAPK1; TP53; NFKB1 |
| hsa05162 | Measles_Homo sapiens_hsa05162 | 2.909E-03 | 1.148E-02 | TP53; NFKB1; TLR2 |
| hsa04932 | Non-alcoholic fatty liver disease (NAFLD)_Homo sapiens_hsa04932 | 3.904E-03 | 1.464E-02 | CASP7; PPARA; NFKB1 |
| hsa04151 | PI3K-Akt signaling pathway_Homo sapiens_hsa04151 | 5.579E-03 | 1.902E-02 | MAPK1; TP53; NFKB1; TLR2 |
| hsa05010 | Alzheimer's disease_Homo sapiens_hsa05010 | 5.256E-03 | 1.863E-02 | CASP7; MAPK1; HSD17B10 |
| hsa05164 | Influenza A_Homo sapiens_hsa05164 | 5.885E-03 | 1.928E-02 | CASP1; MAPK1; NFKB1 |
| hsa05152 | Tuberculosis_Homo sapiens_hsa05152 | 6.168E-03 | 1.928E-02 | MAPK1; NFKB1; TLR2 |
| hsa05202 | Transcriptional misregulation in cancer_Homo sapiens_hsa05202 | 6.361E-03 | 1.947E-02 | TP53; MMP9; NFKB1 |
| hsa05168 | Herpes simplex infection_Homo sapiens_hsa05168 | 6.859E-03 | 2.058E-02 | TP53; NFKB1; TLR2 |
| hsa05203 | Viral carcinogenesis_Homo sapiens_hsa05203 | 9.082E-03 | 2.349E-02 | MAPK1; TP53; NFKB1 |
| hsa05213 | Endometrial cancer_Homo sapiens_hsa05213 | 5.341E-03 | 1.863E-02 | MAPK1; TP53 |
| hsa04010 | MAPK signaling pathway_Homo sapiens_hsa04010 | 1.631E-02 | 3.495E-02 | MAPK1; TP53; NFKB1 |
| hsa04923 | Regulation of lipolysis in adipocytes_Homo sapiens_hsa04923 | 6.171E-03 | 1.928E-02 | FABP4; TSHR |
| hsa05223 | Non-small cell lung cancer_Homo sapiens_hsa05223 | 6.171E-03 | 1.928E-02 | MAPK1; TP53 |
| hsa05014 | Amyotrophic lateral sclerosis (ALS)_Homo sapiens_hsa05014 | 5.143E-03 | 1.863E-02 | CASP1; TP53 |
| hsa04150 | mTOR signaling pathway_Homo sapiens_hsa04150 | 7.055E-03 | 2.075E-02 | MAPK1; HIF1A |
| hsa05214 | Glioma_Homo sapiens_hsa05214 | 8.236E-03 | 2.206E-02 | MAPK1; TP53 |
| hsa05210 | Colorectal cancer_Homo sapiens_hsa05210 | 7.517E-03 | 2.168E-02 | MAPK1; TP53 |
| hsa04725 | Cholinergic synapse_Homo sapiens_hsa04725 | 2.275E-02 | 4.550E-02 | ACHE; MAPK1 |
| hsa04912 | GnRH signaling pathway_Homo sapiens_hsa04912 | 1.567E-02 | 3.406E-02 | MMP2; MAPK1 |
| hsa05231 | Choline metabolism in cancer_Homo sapiens_hsa05231 | 1.907E-02 | 3.918E-02 | MAPK1; HIF1A |
| hsa05218 | Melanoma_Homo sapiens_hsa05218 | 9.761E-03 | 2.400E-02 | MAPK1; TP53 |
| hsa05211 | Renal cell carcinoma_Homo sapiens_hsa05211 | 8.482E-03 | 2.232E-02 | MAPK1; HIF1A |
| hsa04917 | Prolactin signaling pathway_Homo sapiens_hsa04917 | 1.003E-02 | 2.413E-02 | MAPK1; NFKB1 |
| hsa05321 | Inflammatory bowel disease (IBD)_Homo sapiens_hsa05321 | 8.236E-03 | 2.206E-02 | NFKB1; TLR2 |
| hsa04211 | Longevity regulating pathway - mammal_Homo sapiens_hsa04211 | 1.666E-02 | 3.519E-02 | TP53; NFKB1 |
| hsa05146 | Amoebiasis_Homo sapiens_hsa05146 | 1.871E-02 | 3.899E-02 | NFKB1; TLR2 |
| hsa04660 | T cell receptor signaling pathway_Homo sapiens_hsa04660 | 2.014E-02 | 4.083E-02 | MAPK1; NFKB1 |
| hsa04662 | B cell receptor signaling pathway_Homo sapiens_hsa04662 | 1.030E-02 | 2.413E-02 | MAPK1; NFKB1 |
| hsa05323 | Rheumatoid arthritis_Homo sapiens_hsa05323 | 1.534E-02 | 3.384E-02 | MMP1; TLR2 |
| hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 2.313E-02 | 4.566E-02 | ALOX15; MAPK1 |
| hsa05222 | Small cell lung cancer_Homo sapiens_hsa05222 | 1.408E-02 | 3.151E-02 | TP53; NFKB1 |
| hsa05216 | Thyroid cancer_Homo sapiens_hsa05216 | 1.686E-03 | 7.664E-03 | MAPK1; TP53 |
| hsa04920 | Adipocytokine signaling pathway_Homo sapiens_hsa04920 | 9.499E-03 | 2.375E-02 | PPARA; NFKB1 |
| hsa04670 | Leukocyte transendothelial migration_Homo sapiens_hsa04670 | 2.549E-02 | 4.965E-02 | MMP2; MMP9 |
| hsa04623 | Cytosolic DNA-sensing pathway_Homo sapiens_hsa04623 | 7.993E-03 | 2.206E-02 | CASP1; NFKB1 |
| hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 9.240E-03 | 2.349E-02 | CYP2A6; CYP3A4 |
| hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 1.286E-02 | 2.922E-02 | CYP2A6; CYP3A4 |
| hsa05131 | Shigellosis_Homo sapiens_hsa05131 | 8.236E-03 | 2.206E-02 | MAPK1; NFKB1 |
| hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 1.030E-02 | 2.413E-02 | CYP2A6; CYP3A4 |
| hsa04520 | Adherens junction_Homo sapiens_hsa04520 | 1.057E-02 | 2.439E-02 | PTPN1; MAPK1 |
| hsa04964 | Proximal tubule bicarbonate reclamation_Homo sapiens_hsa04964 | 1.059E-03 | 6.355E-03 | CA2; CA4 |
| hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 1.686E-03 | 7.664E-03 | ALOX15; CYP3A4 |
| hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 4.288E-05 | 6.432E-04 | CYP2A6; XDH |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | TP53 |
| H60-H95: Diseases of the ear and mastoid process | Hearing disorder | H90.5 | TP53 |
| I00-I99: Diseases of the circulatory system | Heart failure | I50 | XDH |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | MMP2 |
| C00-D49: Neoplasms | Oral cavity cancer | C00-C08 | TP53 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | PTPN1; FFAR1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | MMP2 |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | ACHE |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA2; ACHE; CA4 |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; CA4 |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | PTPN1; PTPN1; FFAR1; PPARD; NFKB1 |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | TP53; TP53 |
| G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | CASP1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | MMP1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | PTPN1; PPARD; PPARD |
| E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | FFAR1 |
| K00-K95: Diseases of the digestive system | Non-alcoholic fatty liver disease | K76.0 | PPARD |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | HIF1A; TP53; CA9; MAPK1; MMP9; TLR2; MMP2 |
| C00-D49: Neoplasms | Melanoma | C43 | TLR2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | CYP3A4; ACHE |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | CASP1; MMP1 |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; CA1 |
| NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE |
| E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic disorders | E70-E89 | PPARD |
| C00-D49: Neoplasms | Cancer | C00-C96 | HIF1A; TP53; CA1; CA9; MAPK1; MMP9; NFKB1; TLR2; MMP2; ACHE |
| C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | TLR2 |
| NA: NA | Edema | NA | CA2 |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE |
| C00-D49: Neoplasms | Breast cancer | C50 | CA9 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Radiation sickness | T66 | TLR2 |
| N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE |
| K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | MMP9 |
| NA: NA | Upper abdominal bloating | NA | ACHE |
| I00-I99: Diseases of the circulatory system | Restenosis | I51.89 | MAPK1 |
| I00-I99: Diseases of the circulatory system | Renal artery disease | I70.1 | TP53 |
| C00-D49: Neoplasms | Renal cell carcinoma | NA | MMP2 |
| C00-D49: Neoplasms | Renal cancer | C64 | CA9 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Toxicity | T36-T50, T51-T65 | TP53 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 1 diabetes | E10 | PPARD |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE |
| C00-D49: Neoplasms | Prostate cancer | C61 | TLR2 |
| C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | TP53 |
| C00-D49: Neoplasms | Lung cancer | C33-C34 | MMP2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic nephropathy | E11.21 | MMP1 |
| C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | ACHE |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2 |
| K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE |
| A00-B99: Certain infectious and parasitic diseases | Infections | A00-B99 | PTPN1 |
| I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A |
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | PPARD |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricaemia in gout | E79.0, M10 | XDH |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricemia | E79.0 | XDH |
| E00-E89: Endocrine, nutritional and metabolic diseases | Dyslipidaemias | E78 | PPARD; PPARD |
| NA: NA | Dyslipidemia | NA | PPARD |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | XDH |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | ACHE; ACHE; ACHE |
| E00-E89: Endocrine, nutritional and metabolic diseases | Fabry's disease | E75.2 | GLA |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | ACHE |
| L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | CASP1 |
| G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE |
| E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | TLR2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2 |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | TP53 |
| I00-I99: Diseases of the circulatory system | Stroke | I61-I63, I80-I82 | MMP9 |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | CA1; ACHE |
| NA: NA | Colour dead tissues | NA | PTPN1 |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | TP53; MMP9 |
| A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE |
| C00-D49: Neoplasms | Non-small-cell lung cancer | NA | MMP2 |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | HIF1A; CA9 |
| C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR |
| C00-D49: Neoplasms | Thyroid cancer | C73 | TSHR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | PPARD |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE |
| I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | PPARD |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | CA1; CA1; ACHE |
| A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | ACHE |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | TLR2; MMP2 |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2 |
| G00-G99: Diseases of the nervous system G00-G99 | Encephalopathy | G93.4 | XDH |
| C00-D49: Neoplasms | Ovarian cancer | C56 | MMP2 |